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Current status of SLNB in Japan
Sentinel lymph node biopsy (SLNB) has been used in Japan
since about 1998,1 and rapidly came into widespread use.
About half of the major institutions in Japan perform SLNB at
present, and in 1999, the Sentinel Node Navigation Surgery
Society (SNNSS) was established to determine good practice
for SLNB. The society consists of surgeons, radiologists and
pathologists, and its activities include preparation of guidelines,
investigation of the current status of SLNB in Japan by con-
ducting questionnaire surveys, and annual scientific meetings.
In spite of these efforts, there are many issues that need to be
resolved in Japan, including government approval of dyes such
as isosulfan blue, government insurance approval of SLNB,
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education and certification. These issues have arisen because
of the rapid adoption of SLNB, and the SNNSS has not had
enough time to deal with them.
The problem regarding radioisotopes (RIs) is that, by
law, they can only be used in radiologically controlled areas.
However, patients leave the controlled area after injection of
radioactive agents. The situation is the same whether a physi-
cian uses carbon 14, a large amount of 99mTc for bone scinti-
graphy or a small amount of 99mTc for SLNB. Concerns about
the adverse effects of RIs are an important problem for para-
medical staff, but the dose of RI used to perform SLNB is very
small (e.g. about 1/10 to 1/100 of doses used in bone scan and
myocardial perfusion scan), and the measured RI count is very
low compared to the dose recommended by the International
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Commission on Radiological Protection (ICRP).2 Data con-
firm that an operator can perform more than 500 cases a year
according to the ICRP recommendation. In fact, no radiation
exposure was noted at the abdomen of assisting nurses using
the conventional radiation monitor. It is also thought that
pathologists and paramedical staff can perform SLNB safely
in terms of radiation hazard. Paramedical staff and patients
need to be provided with accurate information about RIs.
The entire population of Japan is covered by national
health insurance. Thus, it is important for SLNB to be ap-
proved by the insurance system so that it becomes a routine
procedure. Japanese investigators are asking the government
to approve coverage of SLNB by the national health insurance.
There is no systematic education concerning SLNB in
Japan, and each investigator must obtain information indepen-
dently. A learning curve has been reported to exist for SLNB,3
and we have also noted a learning curve from a questionnaire
survey conducted in Japan.4 It is important to perform SLNB
only after experience has been gained from an adequate num-
ber of cases, but what should be the minimum requirement?
Cox et al reported a decrease in the false-negative rate after 20
cases,3 whereas Sanidas et al reported that while 20 cases are
adequate for breast surgeons, 60 cases should be required for
general surgeons.5 These criteria should be considered care-
fully, because in the experience of 20 cases before routine prac-
tice, there may be about 10 node-positive cases and the false-
negative rate may exceed 10%, even if there was only one false-
negative case. Since false-negative cases occur not only be-
cause of poor surgical technique but because of the method of
pathological examination, thorough education in the surgical,
radiological and pathological techniques is important. The
Japan Society of Nuclear Medicine issued a guideline for RI
use in SLNB in 1999,6 and the SNNSS issued a guideline for
the use of SLNB in 2003.7 However, the application of these
guidelines has never been evaluated, and it is unclear how
many surgeons follow them.
Technical aspects of SLNB in Japan
A questionnaire survey under the auspices of SNNSS in 2002
revealed that the combined method was more popular than
the RI or dye methods alone,8 probably because of the superi-
ority of the combined method in terms of the identification
and false-negative rates, despite some obstacles, including
government regulations and expensive instruments. Several
colloids are used in Japan. Large-particle tin colloid was popu-
lar at first,9 but since nodal uptake was relatively poor because
of the large particle size, small-particle tin colloid,10 phytic
acid11 and rhenium colloid12 are now used, and good results
have been reported for them all. The timing of the RI injection
depends on the colloid used. If a large-particle colloid such
as tin colloid is used, the injection is administered 3–15 hours
before surgery. The RI method allows physicians to confirm
the presence of an SLN preoperatively and to confirm lym-
phatic flow to the internal mammary chain. Peritumoural
injections are performed to detect lymphatic flow to the inter-
nal mammary chain by the RI method. Lymphoscintigraphy is
usually performed after RI injection in Japan.
The blue-dye method is being rapidly adopted in Japan. As
no dye has been formally approved for SLNB in Japan, various
dyes are used.13 Isosulfan blue (Lymphazurin; Ben Venue
Laboratories Inc, Bedford, OH, USA) is a standard dye in the
USA, but because it is not yet approved in Japan, physicians
are forced to import it privately. Patent blue dye has also not
been approved as a drug, and it is prepared in the hospital.
Indocyanine green and indigo carmine have been approved
as testing drugs, so they are easy to use, although their mi-
gration to lymph nodes is poorer than that of other agents.
Blue dye is injected just before the operation. It may be in-
jected intradermally, subcutaneously, peritumourally or sub-
areolarly. Since migration to SLNs is better after intradermal
or subareolar injection than peritumoural injection,14,15 in-
tradermal or subareolar injections are used more frequently.
Current status of SLNB in daily practice
Centres that do not fulfill standard criteria cannot participate
in clinical trials in the USA. Many training courses are held in
the USA, but none have been held in Japan. Each institution
performs SLNB as a routine procedure after approval by its
institutional review board. Many institutions have already
started to perform SLNB without back-up dissection.16 The
existence of a learning curve has been reported, especially with
the blue-dye method, and the importance of training is obvious.
Methods of pathological examination of SLNs
One of the advantages of SLNB is the meticulous examination
of sentinel nodes, because the pathologist can concentrate on
examining only a few SLNs instead of 20–30 axillary nodes.
The issue of micrometastasis arises as a result of meticulous
examination of SLNs. The clinical significance of micro-
metastasis is unclear, and the American Joint Committee on
Cancer staging system for breast cancer revised its general
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rules, with a definition of lymph node metastasis as an isolated
cancer cell nest smaller than 0.2 mm and micrometastasis as
smaller than 2 mm, compared to conventional metastasis as
larger than 2 mm.17 Isolated cancer cell nests are not consid-
ered metastases. However, this definition is not absolute and
it will be necessary to revise it as more data become available in
the future. Currently, many centres diagnose metastasis based
on pathological examination of a single haematoxylin and
eosin (H&E)-stained section. However, many leading institu-
tions examine multiple cut surfaces that have been subjected
to immunohistochemical staining as well as H&E staining.
Viale et al reported that about 64% of metastases to SLNs
were detected by examining one cut surface and about 77%
were detected by examining three cut surfaces.18 Examination
of immunohistochemically-stained sections is usually per-
formed after the operation, and some institutions test for
mRNA,19 such as cytokeratin and carcinoembryonic antigen,
by reverse transcriptase-polymerase chain reaction (RT-PCR)
assay. However, this method is still investigational. When an
SLN is found to be positive intraoperatively, back-up axillary
dissection is generally performed. When an SLN is found to
be positive postoperatively, however, many institutions may
perform axillary dissection, but radiotherapy may be substi-
tuted when the metastasis is subclinical. Usually, no addi-
tional treatment is planned when metastasis is detected by
RT-PCR alone.
Issues of the internal mammary chain
Parasternal lymph node dissection is not usually performed,
since no prognostic benefit has been demonstrated.20 How-
ever, when a positive parasternal lymph node is found, the
prognosis is about the same as for patients with a positive
axillary node, but patients with positive axillary- and paraster-
nal nodes have a poorer outcome than patients who have a
positive axillary node only.21 Thus, examination of the inter-
nal mammary chain may still be of prognostic value. Although
there are no means of detecting lymphatic flow in the indi-
vidual patient, lymphomapping has made it possible to dis-
sect the internal mammary chain in patients with lymphatic
flow to an internal mammary chain alone. Lymphomapping,
however, requires use of RIs, and scintigraphy should be per-
formed before the operation. The injection site is also impor-
tant because colloid particles do not flow through the internal
mammary chain when injected subareolarly or intradermally,
so they must be injected peritumourally. Even when lymphatic
flow in an internal mammary direction is present, no metasta-
sis may be present. A small metastasis to an internal mammary
node may replace the entire node, because internal mammary
nodes are usually small, thereby leading to a false-negative
result. For this reason, internal mammary dissection accord-
ing to lymphomapping is in the developmental phase, and
only a few institutions are performing it investigationally in
Japan.22
SLNB after primary chemotherapy
There have been many recent reports on SLNB after primary
chemotherapy,23–25 but no conclusions can be drawn because
of the small number of cases. According to a summary report,
SLNB after primary chemotherapy seems to be slightly poorer
in terms of identification rate and false-negative rate than
SLNB without primary chemotherapy; thus, SLNB after pri-
mary chemotherapy is still regarded as investigational. There-
fore, some institutions are performing SLNB to confirm the
presence or absence of metastasis in candidates for primary
chemotherapy in Japan as well as in Western countries.26
Other issues in Japan
The most frequent cause of false-negative results is lymph
node metastasis that has replaced the entire lymph node with
cancer cells, and a trial that involves echography, helical com-
puted tomography (CT) and magnetic resonance imaging to
detect lymph nodes substituted by cancer cells preoperatively
is currently under way. SLNB is not indicated in patients with
suspected metastasis based on the results obtained with these
imaging modalities. Some institutions use echo-guided fine-
needle aspiration cytology to rule out SLN metastasis.27
Some investigators are devising other methods to replace
the RI method, for example, using magnetic particles instead
of RI colloid and detecting them using a magnetic probe.28 As
it is difficult to use RIs in some institutions, a trial to detect
lymphatic flow by CT after local injection of contrast medium
is also being conducted.29 This method may allow more pre-
cise detection of SLNs.
Finally, the SLNB technique has rapidly become popular
in Japan, but the rules and/or guidelines and education system
have not kept pace. Guidelines were recently published by the
SNNSS, and SLNB can be performed accurately, irrespective
of the methods. Acquiring experience in performing SLNB is
much more important than the method used. The existence of
a learning curve should be taught, because the dye method will
increase in popularity in Japan in the near future. On the other
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hand, detection methods, definitions and the biological sig-
nificance of micrometastasis are international problems that
should be solved through international discussions.
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